Diagnosis, Treatment, and Outcome Assessment of Septic Cardiomyopathy Using an Integrated Mathematical Model

Use of an Integrated Mathematical Model for the Diagnosis, Treatment and Outcome Assessment of Septic Cardiomyopathy

The goal of this observational study is to evaluate whether a new integrated mathematical model can improve the accuracy of diagnosing septic cardiomyopathy and predicting clinical outcomes in adult patients with suspected septic cardiomyopathy. The study aims to determine whether the integrated mathematical model enhances diagnostic accuracy and improves the prediction of clinical outcomes in these patients.

Study Overview

• Status: Recruiting
• Conditions: Septic Cardiomyopathy

Detailed Description

This multicenter, prospective observational study will enrol adult patients treated for sepsis or septic shock in the intensive care unit (ICU). Eligible patients will be identified based on predefined inclusion and exclusion criteria and enrolled in the study after obtaining informed consent. The primary transthoracic echocardiography will be performed within 48 hours of enrollment to gather detailed echocardiographic data, while key hemodynamic measurements will be recorded simultaneously.

A second transthoracic echocardiography will be conducted within 10 days of the initial evaluation. This follow-up assessment will occur during continued ICU care after discontinuation of vasopressor therapy or during hospitalization in the general ward, depending on the patient's clinical progression. The echocardiographic and hemodynamic parameters from both the initial and follow-up evaluations will be input into a mathematical formula designed to integrate these data into a single cardiovascular estimate. This integrated model will then be used to assess its ability to predict patient outcomes.

Following hospital discharge, patients will be followed for up to one year. During this period, a long-term follow-up assessment will be conducted, during which patients will complete the SF-36 quality of life questionnaire. This follow-up will assess patients' overall health, functional status, frequency of healthcare visits, and need for nursing care. These data will provide insights into the long-term impact of sepsis and septic cardiomyopathy on survivors beyond the acute phase of their illness.

This study will evaluate whether the use of an integrated model that combines clinical parameters with echocardiographic measurements can improve the accuracy of diagnosing septic cardiomyopathy and provide valuable predictions of clinical outcomes. Additionally, the study will assess the course of septic cardiomyopathy and its impact on one-year follow-up outcomes, including patient quality of life. A broadly applicable diagnostic approach could allow for timely treatment adjustments, reduce the burden of sepsis-related complications, and improve overall patient outcomes.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

Study Locations

• Lithuania
  • Vilnius, Lithuania
    • Recruiting
    • Vilnius University Hospital Santaros Klinikos
    • Contact: Tomas Jovaisa, Prof; Phone Number: +37062697567; Email: tomas.jovaisa@santa.lt
    • Contact: Tomas Jovaisa, Prof
    • Contact: Lina Puodziukaite
• Poland
  • Warsaw, Poland
    • Recruiting
    • University Clinical Centre of the Medical University of Warsaw
    • Contact: Mateusz Zawadka, Dr; Phone Number: +48505018394; Email: mateusz.zawadka@wum.edu.pl
    • Contact: Mateusz Zawadka, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients treated for sepsis or septic shock in the Intensive Care Units of two university hospitals.

Description

Inclusion Criteria:

• Age 18 years or older;
• Sepsis according to SEPSIS-3 criteria:
• Suspected/confirmed infection and
• SOFA (Sequential Organ Failure Assessment) score ≥ 2 or qSOFA score ≥ 2;
• Septic shock according to SEPSIS-3 criteria:
• Sepsis is diagnosed and
• Vasopressor infusion is used to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and
• Lactate > 2 mmol/l;
• Cardiovascular support requirement for norepinephrine > 0.1 mcg/kg/min infusion;
• Signed informed consent form (ICF);

Exclusion Criteria:

• Individuals under 18 years of age;
• Has uncompensated cardiovascular disease:
• Cardiogenic shock;
• Congenital heart disease;
• Heart failure NYHA functional class IV;
• Refusal to participate in the study.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of septic cardiomyopathy when comparing a new clinical-echocardiographic model with the standard diagnostic method (left ventricular ejection fraction).	Incidence of septic cardiomyopathy, evaluated by comparing the diagnostic accuracy of a new clinical-echocardiographic model with the standard method, left ventricular ejection fraction (LVEF) measurement. The study will determine whether the new model improves the diagnosis of septic cardiomyopathy in patients with sepsis or septic shock.	From enrollment to the end of one-year follow-up.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessing the severity of septic cardiomyopathy and determining the severity grade.	This will be done by applying clinical and echocardiographic data to the integrated mathematical model, which will then categorize the severity of the condition into predefined severity grades. The assessment aims to provide a more nuanced understanding of the diseases impact on cardiac function and to validate the models ability to stratify patients based on the severity of their condition.	From enrollment to the end of one-year follow-up.
Length of intensive care unit and hospital stay	Total cumulative number of days spent in intensive care unit and hospital	Intensive care unit days spent per patient: within 60 days following intensive care unit admission. Hospital days spent per patient: from admission up to 30 days.
Mortality	Mortality during intensive care unit stay, in hospital and at 1 year	Within 1 year of inclusion
Recovery of cardiac function	Changes in the integrated mathematical model during hospitalization	Within 30 days of inclusion
Long-term health and functional outcomes	Heath-related quality of life assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Assessment of changes in functional capacity, number of visits to healthcare facilities, and the need for nursing care.	Within 1 year of inclusion

Collaborators and Investigators

• Sponsor: Vilnius University
• Collaborators: Vilnius University Hospital Santaros Klinikos

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2024
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: January 16, 2025
• First Submitted That Met QC Criteria: January 24, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 24, 2025
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: Septic shock; Sepsis; Septic cardiomyopathy
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Cardiomyopathies
• Other Study ID Numbers: 2024-3-1574-1032; 2024/3-1574-1032 (Other Identifier: Vilnius Regional Biomedical Research Ethics Comittee)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No